Valuation: Acrux Limited

Market Cap 71.86L 49.61L 43.5L 40.1L 37.54L 70.39L 47Cr 4.82Cr 1.86Cr 23Cr 1.86Cr 1.82Cr 80Cr P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 99.58L 68.75L 60.28L 55.57L 52.02L 97.55L 65Cr 6.68Cr 2.58Cr 32Cr 2.58Cr 2.53Cr 111.15Cr EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day-7.14%
1 week-7.14%
Current month+8.33%
1 month+8.33%
3 months+18.18%
6 months-13.33%
Current year-13.33%
1 week 0.01
Extreme 0.013
0.02
1 month 0.01
Extreme 0.011
0.02
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.84
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 15/02/2015
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-7.14%-7.14%-18.75%-69.77% 49.61L
+0.85%+0.96%+12.24%+78.85% 4.74TCr
+0.79%+2.83%+52.57%+106.39% 3.55TCr
+2.08%+4.18%-2.06%+45.32% 1.23TCr
+1.23%+2.77%+12.69%+91.34% 1.16TCr
-2.10%+0.38%+36.72%+126.29% 888.1Cr
-0.49%+2.87%+22.00%+43.53% 720.73Cr
+1.37%+2.75%+54.59%-8.50% 691.07Cr
+1.18%-0.49%+24.36%+222.65% 644.5Cr
-3.83%-0.76%-35.52%-3.58% 494.11Cr
Average -0.55%+1.69%+15.88%+63.25% 1.41TCr
Weighted average by Cap. +0.67%+2.86%+24.15%+84.45%

Financials

2024 2025
Net sales 50.91L 35.15L 30.82L 28.41L 26.6L 49.87L 33Cr 3.41Cr 1.32Cr 16Cr 1.32Cr 1.29Cr 57Cr 11.9L 8L 7L 7L 6L 11.66L 7.75Cr 79.82L 30.88L 3.83Cr 30.85L 30.18L 13Cr
Net income -58L -40.05L -35.11L -32.37L -30.3L -56.82L -38Cr -3.89Cr -1.51Cr -19Cr -1.5Cr -1.47Cr -65Cr -59.45L -41.05L -35.99L -33.18L -31.06L -58.24L -39Cr -3.99Cr -1.54Cr -19Cr -1.54Cr -1.51Cr -66Cr
Net Debt 8L 5L 5L 4L 4L 7L 4.94Cr 50.91L 19.7L 2.44Cr 19.68L 19.25L 8.47Cr 27.72L 19.14L 16.78L 15.47L 14.48L 27.16L 18Cr 1.86Cr 71.94L 8.92Cr 71.87L 70.3L 31Cr
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
29/26/29 A$0.0130 -7.14% 2,37,052
26/26/26 A$0.0140 +7.69% 7,89,030
25/26/25 A$0.0130 -7.14% 13,27,517
24/26/24 A$0.0140 +7.69% 3,69,855
23/26/23 A$0.0130 -7.14% 22,04,776

Annual profits - Rate of surprise